This approach mirrors how anti-obesity medications are used in clinical practice, where long-term maintenance therapy prevents weight regain
These effects are observed in experimental settings, but there is no established safe dose for human use from clinical trials
Although we were not able to find any studies concerning the effects of VIP on muc5B regulation and/or expression in asthma, since muc5B might be decreased in asthma [119], and VIP might also be decreased, then one speculation is that VIP directly stimulates production of muc5B
However, the route matters: plasma GHK-Cu circulates systemically, while topical GHK-Cu formulations face a bioavailability challenge penetrating the stratum corneum barrier to reach dermal fibroblasts
Scientific literature highlights that both peptides exhibit properties associated with angiogenesis, tissue regeneration, and cellular protection